Bracco group, founded in 1927, is a global leader in diagnostic imaging, committed to advancing healthcare and improving people’s lives by shaping the future of prevention and precision medicine. The company operates in the healthcare sector across more than 100 countries with a workforce of over 4,000 employees and consolidated annual revenues of approximately €2 billion, 88% generated by international markets.

With a strong commitment to innovation — investing around 9% of its reference turnover in Research & Development — Bracco develops and provides a broad portfolio of pharmaceutical products for diagnostic imaging, including contrast agents for X-ray, Computed Tomography (CT), and Magnetic Resonance Imaging (MRI), as well as microbubbles for Contrast Enhanced Ultrasound (CEUS), and Molecular Imaging through radioactive tracers and novel PET imaging agents, alongside AI-based solutions. It is also a global market leader in advanced contrast management technologies for cardiovascular angiography and radiology imaging. Discover more at www.bracco.com.

This infographic is sponsored by Bracco, an Advisory Board member organization. Representatives of Bracco helped select the topics and issues addressed. Advisory Board experts wrote the quick guide, maintained final editorial approval, and conducted the underlying research independently and objectively. Advisory Board does not endorse any company, organization, product, or brand mentioned herein.

To learn more, view our editorial guidelines.